On November 09, 2026, the Stochastic Oscillator for GPCR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 47 instances where the indicator left the oversold zone. In 43 of the 47 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GPCR's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GPCR as a result. In 56 of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for GPCR just turned positive on October 20, 2026. Looking at past instances where GPCR's MACD turned positive, the stock continued to rise in 31 of 37 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where GPCR advanced for three days, in 177 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for GPCR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.071) is normal, around the industry mean (3.498). P/E Ratio (-6.716) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for OCUL turned positive on October 23, 2026. Looking at past instances where OCUL's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where OCUL's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 61 cases where OCUL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +6.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where OCUL advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
OCUL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OCUL as a result. In 66 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The 50-day moving average for OCUL moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCUL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for OCUL entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.785) is normal, around the industry mean (3.498). P/E Ratio (-4.711) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (40.650) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. OCUL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCUL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
OCUL | ||
|---|---|---|
OUTLOOK RATING 1..100 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 76 | |
P/E GROWTH RATING 1..100 | 18 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GPCR | OCUL | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 80% |
| Declines ODDS (%) | 9 days ago 87% | 10 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 89% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GPCR’s FA Score shows that 2 FA rating(s) are green while OCUL’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GPCR’s TA Score shows that 6 TA indicator(s) are bullish while OCUL’s TA Score has 5 bullish TA indicator(s).
GPCR (@Biotechnology) experienced а +6.78% price change this week, while OCUL (@Biotechnology) price change was -3.08% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
OCUL is expected to report earnings on Mar 08, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GPCR has been loosely correlated with WVE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GPCR jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To GPCR | 1D Price Change % | ||
|---|---|---|---|---|
| GPCR | 100% | +1.49% | ||
| WVE - GPCR | 64% Loosely correlated | -2.01% | ||
| KYMR - GPCR | 63% Loosely correlated | -1.60% | ||
| OCUL - GPCR | 43% Loosely correlated | -3.50% | ||
| FULC - GPCR | 41% Loosely correlated | N/A | ||
| OLMA - GPCR | 39% Loosely correlated | -1.22% | ||
More | ||||
A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with AMLX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To OCUL | 1D Price Change % | ||
|---|---|---|---|---|
| OCUL | 100% | -3.50% | ||
| AMLX - OCUL | 47% Loosely correlated | +2.32% | ||
| KYMR - OCUL | 44% Loosely correlated | -1.60% | ||
| GPCR - OCUL | 43% Loosely correlated | +1.49% | ||
| WVE - OCUL | 42% Loosely correlated | -2.01% | ||
| REPL - OCUL | 37% Loosely correlated | +4.58% | ||
More | ||||